# Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma

> **NCT00535951** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 18 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Mesothelioma

## Interventions

- **DRUG:** LBH589

## Key facts

- **NCT ID:** NCT00535951
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2009-01
- **Final completion:** —
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00535951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00535951, "Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT00535951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*